Insmed Financials - Benzinga

Insmed Inc

INSMNASDAQ

Trade with Public

Trade with Public

$117.83

-3.72-3.06%

In chiusura: Sep 25, 5:00 PM EST

$117.83

N/A

Post-mercato: 4:00 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Insmed Financials

Insmed (INSM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate

Insmed (NASDAQ:INSM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.73) by 91.78 percent. This is a 96.47 percent increase over losses of $(1.70) per share from the same

Benzinga Newsdesk

PRO
Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est

Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion vs $1.705 billion estimate.

Benzinga Newsdesk

Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today

U.S. stocks drifted near records Thursday as oil slipped on Iran-Hormuz peace hopes. Coinbase, Airbnb and CoreWeave on deck after the close.

Piero Cingari

PRO
Insmed Affirms FY2026 Sales Guidance of $1.450B-$1.470B vs $1.699B Est

Insmed (NASDAQ:INSM) affirms FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.450 billion-$1.470 billion vs $1.699 billion estimate.

Benzinga Newsdesk

PRO
Insmed Q1 EPS $(0.76) Beats $(0.97) Estimate, Sales $305.964M Beat $303.298M Estimate

Insmed (NASDAQ:INSM) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.97) by 21.65 percent. This is a 46.48 percent increase over losses of $(1.42) per share from the same

Benzinga Newsdesk

PRO
CORRECTION: Insmed Sees FY2026 Sales $1.450B-$1.470B vs $1.372B Est

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved